Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atebimetinib · 1 trial · 8 indications
The OS of participants with atebimetinib in combination with mGnP versus GnP
| Arm | Type | Description |
|---|---|---|
| Atebimetinib + mGnP | EXPERIMENTAL | Atebimetinib in combination with modified gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma |
| GnP | ACTIVE_COMPARATOR | Standard of care gemcitabine and nab-paclitaxel for first line pancreatic adenocarcinoma |
| Name | Type | Description |
|---|---|---|
| Atebimetinib | DRUG | Once daily oral tablets |
| GnP | DRUG | Standard of care regimen for intravenous infusions of gemcitabine and nab-paclitaxel weekly for three weeks followed by one week without an infusion |
| mGnP | DRUG | Biweekly intravenous infusions of chemotherapy (gemcitabine and nab-paclitaxel) |
Inclusion Criteria: * Must be ≥18 years of age * Must have confirmed diagnosis according to AJCC staging as follows: * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participants must be treatment...
Top 20 of 73 competitors